真菌变应原疫苗治疗变应性支气管哮喘的临床研究

目的 评价真菌疫苗特异性免疫治疗变应性支气管哮喘(简称哮喘)的临床疗效.方法 选择60例真菌过敏的轻、中度哮喘患者临床观察1年,治疗组(36例)和对照组(24例)分别皮下注射真菌变应原疫苗和盐酸组胺.观察治疗前后症状评分、用药计分、PD20-FEV1、PEF、FEV1pred%等指标.并进行统计分析.结果 两组治疗后症状评分均有所下降,但差异无统计学意义;与治疗前比较治疗组补救药物计分下降,PD20-FEV1增加,差异有统计学意义(P<0.01);两组PEF、FEV1pred%较治疗前差异均无统计学意义.治疗期间未发生一例严重不良反应事件.结论 对轻至中度的哮喘患者用真菌变应原疫苗进行特异性免疫治疗有效、安全.

Effects of specific immunotherapy with fungi allergen vaccine in allergic asthmatic

Objective To evaluate the clinical efficacy and safety of specific immunotherapy(SIT) with fungi allergen vaccine on allergic bronchial asthma(asthma). Methods Sixty patients of mild to moderate asthma who were allergic to fungi allergen, were randomly allocated to the active group ( n = 36) and the control group ( n = 24) were observed. The active group received SIT with a standardized fungi allergen vaccine,while the control group received a placebo containing histamine dihydrochlo-ride by subcutaneous injections for a year. Results The symptom scores in a year between the active group and the control group were no significant difference comparing with the year before. The mean daily medication scores in a year were significant lower than those of the year before, while the control group did not show significant difference. A significant difference was found in provoking dose dcreasing FEV1by 200% (PD20-FEV1) between the active group and the control group. After 1-year treatment,no significant differences were found in morning and evening peak expirating flow, expiratory volume in one second of predicted value (FEV1 pred%) between the active group and the control group. No any severe systemic therapy adverse reaction was shown in the study. Conclusions One year specific immunotherapy with standardized fungi allergen vaccine significantly improved symptoms and reduced medication use in mild to moderate allergic asthmatic patients. SIT also reduced brochial hyperreactivity. SIT with standardized fungi allergen vaccine is a safe treatement.